Published in Am J Pathol on March 01, 2002
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One (2009) 2.36
Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol (2009) 1.78
Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res (2005) 1.36
Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol (2003) 1.20
Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol (2005) 1.08
Endothelin receptors as novel targets in tumor therapy. J Transl Med (2004) 1.07
Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res (2005) 1.07
A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS One (2012) 1.07
Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment. Biochem J (2011) 1.05
Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol (2009) 1.05
Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo. Int J Mol Sci (2011) 1.04
Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer (2006) 0.99
Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J Cancer Res Clin Oncol (2004) 0.97
Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis. Virchows Arch (2004) 0.94
Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor gamma in epithelial ovarian tumours. Br J Cancer (2004) 0.93
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer (2008) 0.93
An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas. BMC Cancer (2011) 0.93
Age dependent increase in prostaglandin pathway coincides with onset of ovarian cancer in laying hens. Prostaglandins Leukot Essent Fatty Acids (2012) 0.86
Loss of the EP2 prostaglandin E2 receptor in immortalized human keratinocytes results in increased invasiveness and decreased paxillin expression. Am J Pathol (2002) 0.84
Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers (Basel) (2010) 0.83
Expression of peroxisome proliferator activated receptor gamma and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma. J Clin Pathol (2006) 0.81
Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination. Clin Exp Metastasis (2004) 0.81
Effects of cyclooxygenase inhibitors in combination with taxol on expression of cyclin D1 and Ki-67 in a xenograft model of ovarian carcinoma. Int J Mol Sci (2012) 0.81
Selective cyclooxygenase inhibitors increase paclitaxel sensitivity in taxane-resistant ovarian cancer by suppressing P-glycoprotein expression. J Gynecol Oncol (2013) 0.81
Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo. Int J Mol Sci (2010) 0.80
Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene (2015) 0.78
Cyclooxygenase-2 inhibitors in gynecologic practice. Clin Med Res (2003) 0.78
Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice. Oncol Lett (2012) 0.77
Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget (2015) 0.77
Anti-inflammatory effects of fish oil in ovaries of laying hens target prostaglandin pathways. Lipids Health Dis (2013) 0.76
Molecular and Cellular Mechanisms of Antitumor Immune Response Activation by Dendritic Cells. Acta Naturae (2016) 0.75
High and low frequency subharmonic imaging of angiogenesis in a murine breast cancer model. Ultrasonics (2015) 0.75
The function of COX-2 in human ovarian carcinoma. Am J Pathol (2003) 0.75
CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. Br J Cancer (2016) 0.75
[Molecular profiling and predictive signatures. Biomarker analysis in ovarian cancer]. Pathologe (2008) 0.75
Cancer statistics, 2000. CA Cancer J Clin (2000) 12.32
Aspirin use and reduced risk of fatal colon cancer. N Engl J Med (1991) 7.85
Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell (1996) 7.46
Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 7.25
Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell (1995) 6.69
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A (1997) 4.84
Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell (1997) 4.69
Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology (1994) 4.27
Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell (1995) 4.17
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res (1998) 3.79
cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci U S A (1992) 3.65
Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature (1995) 3.44
Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res (1998) 3.20
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res (1998) 3.11
Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res (1999) 3.00
Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res (1997) 2.99
Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res (1998) 2.92
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res (1983) 2.90
Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features--problems involved in the architectural grading system. Gynecol Oncol (1998) 2.50
Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res (1999) 2.40
Recent advances in chemoprevention of cancer. Science (1997) 2.30
Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst (1998) 2.26
Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res (1998) 2.11
Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst (1998) 2.09
Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology (1999) 2.05
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res (2001) 1.93
Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol (1999) 1.83
Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res (2000) 1.81
Over-the-counter analgesics and risk of ovarian cancer. Lancet (1998) 1.59
Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. J Clin Oncol (2000) 1.51
Expression of cyclooxygenase-2 in prostate carcinoma. Cancer (2000) 1.49
Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res (1991) 1.39
Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res (2001) 1.28
A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev (2000) 1.27
Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary. J Natl Cancer Inst (1984) 1.24
Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol (2001) 1.22
Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol (2000) 1.15
Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas. J Histochem Cytochem (1998) 0.96
The induction of cyclooxygenase-2 by 17beta-estradiol in endothelial cells is mediated through protein kinase C. Inflamm Res (2000) 0.93
Apoptotic index in ovarian carcinoma: correlation with clinicopathologic factors and prognosis. Gynecol Oncol (1997) 0.92
Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. Int J Mol Med (2001) 0.92
Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. Cancer Lett (1999) 0.89
p53 and related proteins in epithelial ovarian cancer. Eur J Cancer (2000) 0.88
Regulation of cyclooxygenase-2 and prostaglandin F synthase gene expression by steroid hormones and interferon-tau in bovine endometrial cells. Endocrinology (1998) 0.86
The regulation by ovarian steroids of prostaglandin synthesis and prostaglandin-induced contractility in non-pregnant rat myometrium. Modulating effects of isoproterenol. J Endocrinol (2001) 0.84
Different features of angiogenesis between ovarian and breast carcinoma. Cancer Lett (2001) 0.83
[Prostaglandins E in the primary tumor, metastases, and ascitic fluid of patients with ovarian cancer]. Biull Eksp Biol Med (1997) 0.83
Formation of prostaglandins by ovarian carcinomas. Prostaglandins (1985) 0.80
Effect of hormonal status on the expression of the cyclooxygenase 1 and 2 genes and prostaglandin synthesis in rat mammary glands. Prostaglandins Other Lipid Mediat (1998) 0.79
Tumor angiogenesis and thymidine phosphorylase expression in ovarian carcinomas including serous surface papillary adenocarcinoma of the peritoneum. Int J Gynecol Pathol (2000) 0.77
Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med (2009) 5.63
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone. Proc Natl Acad Sci U S A (2005) 2.73
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One (2009) 2.36
Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry. Appl Immunohistochem Mol Morphol (2009) 2.22
Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer (2008) 2.10
Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol (2008) 2.09
Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg (2009) 2.06
Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol (2010) 2.04
Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol (2003) 2.04
CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol (2002) 1.85
Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res (2004) 1.79
Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest (2010) 1.78
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
High-frequency oscillatory ventilation reduces lung inflammation: a large-animal 24-h model of respiratory distress. Intensive Care Med (2007) 1.68
Disparities between male and female patients with thyroid cancers: sex difference or gender divide? Clin Endocrinol (Oxf) (2006) 1.67
The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer (2009) 1.60
Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol (2006) 1.59
Aqp2-expressing cells give rise to renal intercalated cells. J Am Soc Nephrol (2013) 1.59
Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension (2011) 1.59
Metaplasticity of amygdalar responses to the stress hormone corticosterone. Proc Natl Acad Sci U S A (2010) 1.58
Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res (2004) 1.58
Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur Urol (2002) 1.56
Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol (2011) 1.55
Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer (2003) 1.55
An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res (2010) 1.55
Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proc Natl Acad Sci U S A (2009) 1.54
Impairment of sodium balance in mice deficient in renal principal cell mineralocorticoid receptor. J Am Soc Nephrol (2007) 1.51
Recurrent inguinal hernia: disease of the collagen matrix? World J Surg (2002) 1.48
Reduced nitric oxide in sinus epithelium of patients with radiologic maxillary sinusitis and sepsis. Am J Respir Crit Care Med (2003) 1.46
Decreased collagen type I/III ratio in patients with recurring hernia after implantation of alloplastic prostheses. Langenbecks Arch Surg (2003) 1.45
Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog (2007) 1.44
HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer (2009) 1.43
Re: "A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1," Int J Gyn Pathol 2012 May;31: 264-271. Int J Gynecol Pathol (2013) 1.40
Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin Cancer Res (2008) 1.37
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat (2011) 1.32
Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. Eur Heart J (2013) 1.31
Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. Int J Cancer (2005) 1.27
Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol (2011) 1.27
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol (2012) 1.27
Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Eur J Cancer (2013) 1.26
Functional and morphologic properties of a modified mesh for inguinal hernia repair. World J Surg (2002) 1.23
Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia. Stroke (2010) 1.22
Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia (2008) 1.19
Inducible gene inactivation in neurons of the adult mouse forebrain. BMC Neurosci (2007) 1.19
Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. Int J Cancer (2002) 1.18
Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells. J Mol Med (Berl) (2005) 1.18
Inducible expression of coding and inhibitory RNAs from retargetable genomic loci. Nucleic Acids Res (2009) 1.17
Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. J Transl Med (2012) 1.16
IDEAL in meshes for prolapse, urinary incontinence, and hernia repair. Surg Innov (2013) 1.16
Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. BMC Med (2007) 1.15
Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS One (2008) 1.14
The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. Clin Exp Metastasis (2012) 1.13
BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol (2012) 1.12
Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation (2011) 1.12
Activation of an endogenous suicide response after perturbation of rRNA synthesis leads to neurodegeneration in mice. J Neurosci (2008) 1.12
Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol (2004) 1.11
Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. Mod Pathol (2006) 1.08
Lymph node dissection in the lateral neck for completion in central node-positive papillary thyroid cancer. Surgery (2008) 1.08
Histological analysis of silicone breast implant capsules and correlation with capsular contracture. Biomaterials (2003) 1.08
Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization. Hum Pathol (2002) 1.07
Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis. Int J Oncol (2003) 1.07
High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol (2010) 1.06
Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene (2003) 1.06
Impaired balance of type I and type III procollagen mRNA in cultured fibroblasts of patients with incisional hernia. Surgery (2002) 1.05
Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am J Surg Pathol (2011) 1.04
Calculator for ovarian carcinoma subtype prediction. Mod Pathol (2010) 1.04
Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg (2007) 1.03
Aberrant right subclavian artery as a new cardiac sign in second- and third-trimester fetuses with Down syndrome. Am J Obstet Gynecol (2005) 1.03
Factors influencing the agreement on histopathological assessments of breast biopsies among pathologists. Histopathology (2011) 1.01
Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer (2004) 1.01
Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch Surg (2007) 1.00
Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer. Cancer Lett (2006) 1.00
Postnatal glucocorticoid excess due to pituitary glucocorticoid receptor deficiency: differential short- and long-term consequences. Endocrinology (2009) 0.99
Evidence of complete hydrophobic coating of bombesin by trifluoroethanol in aqueous solution: an NMR spectroscopic and molecular dynamics study. Chemistry (2002) 0.99
Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma. Int J Gynecol Pathol (2006) 0.99
Deleterious effect of zinc in a pig model of acute endotoxemia. J Invest Surg (2004) 0.99
Medicolegal liability in pathology: an international perspective. Semin Diagn Pathol (2007) 0.98
Analysis of PIK3CA mutations in breast cancer subtypes. Appl Immunohistochem Mol Morphol (2014) 0.98
Nucleolin as activator of human papillomavirus type 18 oncogene transcription in cervical cancer. J Exp Med (2002) 0.98
Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. Oncogene (2005) 0.98